Adial Pharmaceuticals, Inc. (ADIL) — Financial statements
Income statement, balance sheet, and cash flow for Adial Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00↓100.0% | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00↑100.0% | -0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 3↓18.9% | 3↑154.9% | 1↓35.0% | 2↓76.8% | 8 | |
| General & Administrative Expenses | 5↑2.5% | 5↓10.1% | 6↓36.9% | 9↓4.7% | 9 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 5↑2.5% | 5↓10.1% | 6↓36.9% | 9↓4.7% | 9 | |
| Other Expenses | 0.00 | 0.00↑100.0% | -0.00 | 0.00↓100.0% | 2 | |
| Operating Expenses | 8↓5.9% | 8↑20.3% | 7↓36.6% | 11↓43.7% | 19 | |
| Total Costs & Expenses | 8↓5.9% | 8↑20.3% | 7↓36.6% | 11↓43.7% | 19 | |
| Operating Results | ||||||
| Operating Income | -8↑5.9% | -8↓20.3% | -7↑36.6% | -11↑43.7% | -19 | |
| Depreciation & Amortization | 0.00↑0.0% | 0.00↑0.2% | 0.00↑0.0% | 0.00↓99.0% | 0.06 | |
| EBITDA | -8↑5.9% | -8↓18.3% | -7↑35.5% | -11↑38.6% | -18 | |
| EBIT | -8↑5.9% | -8↓18.3% | -7↑35.5% | -11↑38.8% | -18 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.15↓16.3% | 0.18↑156.0% | 0.07↑10.2% | 0.06↑868.6% | 0.01 | |
| Interest Income | 0.15↓16.3% | 0.18↑156.0% | 0.07↑10.2% | 0.06↑868.6% | 0.01 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00↓100.0% | 0.11 | 0.00↑100.0% | -2 | |
| Other Income / Expenses | -0.18↑96.4% | -5↓4211.8% | -0.11↓279.9% | 0.06↑127.7% | -0.23 | |
| Income Before Tax | -8↑39.6% | -13↓88.5% | -7↑35.1% | -11↑44.7% | -20 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.09 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -8↑39.6% | -13↓88.5% | -7↑35.1% | -11↑44.4% | -19 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00↑100.0% | -2 | 0.00 | |
| Net Income | -8↑39.6% | -13↓88.5% | -7↑45.0% | -13↑34.5% | -19 | |
| Bottom-Line Net Income | -8↑39.6% | -13↓70.3% | -8↑39.1% | -13↑34.5% | -19 | |
| EPS (Basic) | -11.93↑32.8% | -17.75↑86.9% | -136.00↑54.6% | -299.50↑54.1% | -653.00 | |
| EPS (Diluted) | -11.93↑32.8% | -17.75↑86.9% | -136.00↑54.6% | -299.50↑54.1% | -653.00 | |
| Weighted Average Shares | 0.67↓10.1% | 0.74↑1204.8% | 0.06↑34.0% | 0.04↑43.0% | 0.03 | |
| Weighted Average Diluted Shares | 0.67↓10.1% | 0.74↑1204.8% | 0.06↑34.0% | 0.04↑43.0% | 0.03 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.